ReviewAdvanced drug delivery reviews2017
Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.
Review in Advanced drug delivery reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 201 citations in OpenAlex.
- First-in-Human Study of the Carbohydrate NanoparticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Layer by Layer Engineered Lipid-Based Nanocarriers for Therapeutic Delivery and Next-Generation Design.Pharmaceutics · 2026Review
- The Application of Radiolabeled Mesoporous Silica Nanoparticles in Molecular Imaging.Molecules (Basel, Switzerland) · 2026Review
- Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Radiolabeled Iron-Based Nanomaterials for Cancer Diagnosis and Therapy.International journal of nanomedicine · 2026Review
- CT-Based Attenuation Correction Algorithm for Quantitative L-Shell X-Ray Fluorescence Imaging of Gold Nanoparticles in Murine Tumor Tissues.Diseases (Basel, Switzerland) · 2025Article
- Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.Future oncology (London, England) · 2025Review
- Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers.European journal of nuclear medicine and molecular imaging · 2025Article
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- Design and Biodistribution of PEGylated Core-Shell X-ray Fluorescent Nanoparticle Contrast Agents.ACS applied materials & interfaces · 2025Article
- Advancements in nanotechnology for diagnostics: a literature review, part II: advanced techniques in nuclear and optical imaging.Nanomedicine (London, England) · 2025Review
- Decorrelation Time Mapping as an Analysis Tool for Nanobubble-Based Contrast Enhanced Ultrasound Imaging.IEEE transactions on medical imaging · 2024Article
- [Molecules (Basel, Switzerland) · 2024Review
- Iterative nanoparticle bioengineering enabled by x-ray fluorescence imaging.Science advances · 2024Article
- Deep learning for automatic organ and tumor segmentation in nanomedicine pharmacokinetics.Theranostics · 2024Article
- Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.Immunotherapy advances · 2024Review
- Ligand-based active targeting strategies for cancer theranostics.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- New Insights and Potential Therapeutic Interventions in Metabolic Diseases.International journal of molecular sciences · 2023Review
- Nano magnetic-based ELISA and nano magnetic-based latex agglutination test for diagnosis of experimental trichinellosis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- Nano-biotechnology in tumour and cancerous disease: A perspective review.Journal of cellular and molecular medicine · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Development of novel imaging probes for cancer diagnosis is critical for early disease detection and management. The past two decades have witnessed a surge in the development and evolution of radiolabeled nanoparticles as a new frontier in personalized cancer nanomedicine. The dynamic synergism of positron emission tomography (PET) and nanotechnology combines the sensitivity and quantitative nature of PET with the multifunctionality and tunability of nanomaterials, which can help overcome certain key challenges in the field. In this review, we discuss the recent advances in radionanomedicine, exemplifying the ability to tailor the physicochemical properties of nanomaterials to achieve optimal in vivo pharmacokinetics and targeted molecular imaging in living subjects. Innovations in development of facile and robust radiolabeling strategies and biomedical applications of such radionanoprobes in cancer theranostics are highlighted. Imminent issues in clinical translation of radiolabeled nanomaterials are also discussed, with emphasis on multidisciplinary efforts needed to quickly move these promising agents from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.